Land: Nya Zeeland
Språk: engelska
Källa: Medsafe (Medicines Safety Authority)
Tigecycline 50mg
Juno Pharmaceuticals NZ Limited
50 mg
Powder for injection
Active: Tigecycline 50mg Excipient: Arginine Hydrochloric acid Nitrogen Sodium hydroxide
Prescription
Tigecycline Juno is indicated for the treatment of the following infections in adults: - Complicated skin and skin structure infections, including those with methicillin-resistant Staphylococcus aureus (MRSA), where there is suspected or proven resistance to, intolerance of or there are co-morbidities preventing the use of, other available agents. - Complicated intra-abdominal infections, where there is suspected or proven resistance to, intolerance of, or there are co-morbidities preventing the use of, other available agents.
Package - Contents - Shelf Life: Combination pack, 10 vials (50 mg/ 5mL) per cardboard carton. - 10 dose units - 24 months from date of manufacture stored at or below 25°C - Vial, glass, Type I glass vial, 5 mL - 50 mg - 24 months from date of manufacture stored at or below 25°C
2017-09-28
TIGECYCLINE JUNO Datasheet v1.1 Page 1 of 21 NEW ZEALAND DATA SHEET 1. PRODUCT NAME Tigecycline Juno 50 mg Powder for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOISTION Each 5 mL glass vials of Tigecycline contains 50 mg tigecycline lyophilised powder for intravenous infusion. For the full list of excipients, see SECTION 6.1 . 3. PHARMACEUTICAL FORM Powder for intravenous infusion. Orange to orange-red lyophillised cake or powder. The reconstituted solution is orange-red, essentially free of particulate matter. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Tigecycline is indicated for the treatment of the following infections in adults: • Complicated skin and skin structure infections, including those with methicillin-resistant Staphylococcus aureus (MRSA), where there is suspected or proven resistance to, intolerance of, or there are co-morbidities preventing the use of, other available agents. • Complicated intra-abdominal infections, where there is suspected or proven resistance to, intolerance of, or there are co-morbidities preventing the use of, other available agents. 4.2 DOSE AND METHOD OF ADMINISTRATION _ADULT_ The recommended dosage regimen for tigecycline is an initial dose of 100 mg, followed by 50 mg every 12 hours. Intravenous (IV) infusions of tigecycline should be administered over approximately 30 to 60 minutes every 12 hours. The recommended duration of treatment with tigecycline for complicated skin and skin structure infections or for complicated intra-abdominal infections is 5 to 14 days. The duration of therapy should be guided by the severity and site of the infection and the patient’s clinical and bacteriological progress. _CHILDREN AND ADOLESCENT_ Safety and effectiveness in patients under 18 years of age have not been established. Therefore, use in patients under 18 years of age is not recommended. TIGECYCLINE JUNO Datasheet v1.1 Page 2 of 21 _ELDERLY_ No dosage adjustment is necessary in elderly patients. _HEPATIC IMPAIRMENT_ No dosage adjustment is necessary in patients Läs hela dokumentet